Use of dose-volume histograms for metabolic response prediction in hepatocellular carcinoma patients undergoing transarterial radioembolization with Y-90 resin microspheres
- PMID: 38647875
- DOI: 10.1007/s12149-024-01926-4
Use of dose-volume histograms for metabolic response prediction in hepatocellular carcinoma patients undergoing transarterial radioembolization with Y-90 resin microspheres
Abstract
Introduction: Voxel-based dosimetry offers improved outcomes in the treatment of hepatocellular carcinoma (HCC) with transarterial radioembolization (TARE) using glass microspheres. However, the adaptation of voxel-based dosimetry to resin-based microspheres has been poorly studied, and the prognostic relevance of heterogeneous dose distribution remains unclear. This study aims to explore the use of dose-volume histograms for resin microspheres and to determine thresholds for objective metabolic response in HCC patients treated with resin-based TARE.
Methods: We retrospectively reviewed HCC patients who underwent TARE with Y-90-loaded resin microspheres in our institution between January 2021 and December 2022. Voxel-based dosimetry was performed on post-treatment Y-90 PET/CT images to extract parameters including mean dose absorbed by the tumor (mTD), the percentage of the targeted tumor volume (pTV), and the minimum doses absorbed by consecutive percentages within the tumor volume (D10, D25, D50, D75, D90). Assessment of metabolic response was done according to PERCIST criteria with F-18 FDG PET/CT imaging at 8-12 weeks after the treatment.
Results: This study included 35 lesions targeted with 22 TARE sessions in 19 patients (15 males, 4 females, mean age 60 ± 13 years). Objective metabolic response was achieved in 43% of the lesions (n = 15). Responsive lesions had significantly higher mTD, pTV, and D25-D90 values (all p < 0.05). Optimal cut-off values for mTD, pTV, and D50 were 94.6 Gy (sensitivity 73%, specificity 70%, AUC 0.72), 94% (sensitivity 73%, specificity 55%, AUC 0.64), and 91 Gy (sensitivity 80%, specificity 80%, AUC 0.80), respectively.
Conclusion: Parameters derived from dose-volume histograms could offer valuable insights for predicting objective metabolic response in HCC patients treated with resin-based TARE. If verified with larger prospective cohorts, these parameters could enhance the precision of dose distribution and potentially optimize treatment outcomes.
Keywords: Dose–volume histogram; Hepatocellular carcinoma; Transarterial radioembolization.
© 2024. The Author(s), under exclusive licence to The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine.
Similar articles
-
Dosimetric optimization and evaluation of hepatocellular carcinoma treatment effect prediction in Y-90 radioembolization.Phys Med. 2025 Jun;134:105000. doi: 10.1016/j.ejmp.2025.105000. Epub 2025 May 9. Phys Med. 2025. PMID: 40347554
-
Yttrium-90 Radiation Segmentectomy of Hepatocellular Carcinoma: A Comparative Study of the Effectiveness, Safety, and Dosimetry of Glass-Based versus Resin-Based Microspheres.J Vasc Interv Radiol. 2023 Jul;34(7):1226-1234. doi: 10.1016/j.jvir.2023.02.030. Epub 2023 Mar 21. J Vasc Interv Radiol. 2023. PMID: 36958669
-
Voxel-based tumor dose correlates to complete pathologic necrosis after transarterial radioembolization for hepatocellular carcinoma.Eur J Nucl Med Mol Imaging. 2024 Oct;51(12):3744-3752. doi: 10.1007/s00259-024-06813-8. Epub 2024 Jun 24. Eur J Nucl Med Mol Imaging. 2024. PMID: 38913189
-
Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.Int J Clin Pract. 2017 Nov;71(11). doi: 10.1111/ijcp.12972. Epub 2017 Jul 30. Int J Clin Pract. 2017. PMID: 28758319 Review.
-
Optimizing Yttrium-90 Radioembolization Dosimetry for Hepatocellular Carcinoma: A Korean Perspective.Korean J Radiol. 2025 Jul;26(7):688-703. doi: 10.3348/kjr.2025.0308. Epub 2025 Jun 4. Korean J Radiol. 2025. PMID: 40527741 Free PMC article. Review.
Cited by
-
Dose-response relationships in Y90 resin microsphere radioembolization for patients with hepatocellular carcinoma: insights from a Brazilian cohort.Einstein (Sao Paulo). 2025 May 2;23:eAO1287. doi: 10.31744/einstein_journal/2025AO1287. eCollection 2025. Einstein (Sao Paulo). 2025. PMID: 40332181 Free PMC article.
References
-
- Dancey JE, Shepherd FA, Paul K, Sniderman KW, Houle S, Gabrys J, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med. 2000;41(10):1673–81. - PubMed
-
- Ho S, Lau W, Leung T, Chan M, Ngar Y, Johnson P, Li A. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med Mol Imaging. 1996;23:947–52. - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical